Table 2.
Patient, Tumor and Treatment Characteristics of All Recurrences
| Age at diag.(yrs) | Histo | Primary stage | Tumor grade | Tumor size (cm) | LVI | Site of recur. | Time to recur. (mos.) | BT dose (Gy) | Cum. EQD2 (Gy) | |
|---|---|---|---|---|---|---|---|---|---|---|
| MR-guided ISBT | 38 | SCC | IIB | 2 | 5.3 | Yes | Distant (peritoneum) | 7 | 34 | 84.92 |
| 59 | SCC | IIIB | 2 | 6 | No | Rectum/anus | 57 | 33.75 | 82.92 | |
| 49 | Adenoca | IVA | 3 | 8 | Yes | Distant (lung) | 26 | 30 | 81.75 | |
| 25 | SCC | IIB | 2 | 4.7 | No | Left SCV LN, RP LNs | 17 | 27.5 | 83.18 | |
| 58 | SCC | IIIB | 1 | 10 | Yes | Aortocaval LN | 4 | 27.5 | 79.77 | |
| 41 | SCC | IVA | 3 | 4 | Yes | Liver, spleen | 18 | 17.6 | 74.22 | |
| 33 | SCC | IIIB | 1 | 6 | Yes | Bone metastases | 6 | 29.75 | 82.98 | |
| 29 | SCC | IIIB | 2 | 7.3 | Yes | Parametrium | 5.5 | 27 | 82.19 | |
| 29 | SCC | IIIB | 3 | 7.8 | Yes | Pelvic LN | 1.5 | 31.5 | 82.19 | |
| CT-guided ISBT | 52 | SCC | IVA | 3 | 6.7 | No | Distant (lung) | 3 | 30 | 84.3 |
| 67 | SCC | IIIA | 3 | 3 | Yes | Cervix, PAN | 5 | 33.5 | 83.9 | |
| 60 | SCC | IVB | 2 | 7.6 | NI | Distant (lung) | 2 | 28 | 83.9 | |
| 60 | SCC | IIA | 2 | 2.9 | NI | Pelvic nodule, bladder | 14.5 | 27.5 | 79.8 | |
| 43 | SCC | IVA | 3 | 3.6 | Yes | Uterus, aortocaval LN | 5 | 27.5 | 79.8 | |
| 43 | SCC | IVB | NI | 7.8 | NI | Distant prog NOS | 4 | 31.5 | 79.4 | |
| 43 | Adenoca | IIB | 3 | 7.3 | NI | PAN, RP LNs | 5 | 27 | 77.9 | |
| 63 | SCC | IIIB | 2 | 7.4 | NI | Axillary LN | 27 | 31.5 | 79.7 | |
| 34 | Adenoca | IB2 | 3 | 7.3 | NI | PAN | 4 | 33.75 | 82.9 |
Key: ISBT, Interstitial brachytherapy; Histo, Histology; SCC, Squamous cell carcinoma; Adenoca, Adenocarcinoma; Adenosq, Adenosquamous; Recur, Recurrent; BT, Brachytherapy; abd, abdominal; LN, lymph node; PAN, Para-aortic node; NI, Not identified; prog, progression; SCV, Supraclavicular; NOS, not otherwise specified; italicized refers to local recurrence